The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

@article{Abboud2013ThePO,
  title={The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.},
  author={Camille N. Abboud and Ellin Berman and Adam Daniel Cohen and Jorge E Cortes and Daniel J. Deangelo and Michael Werner Nikolaus Deininger and Steven Michael Devine and Brian J. Druker and Amir T Fathi and Elias Jabbour and Madan H. Jagasia and Hagop M Kantarjian and Jean Khoury and Pierre Laneuville and Richard S. Larson and Jeffrey Howard Lipton and Joseph O. Moore and Tariq I Mughal and Susan O’Brien and Javier Pinilla-Ibarz and Alfonso Quint{\'a}s-Cardama and Jerald P Radich and V. L. Suvarchala Reddy and Charles A Schiffer and Neil Pravin Shah and Paul J. Shami and Richard T. Silver and David Scott Snyder and Richard M. Stone and Moshe Talpaz and Ayalew Tefferi and Richard A. Van Etten and Meir Wetzler and Elisabetta Abruzzese and Jane F Apperley and Massimo Breccia and Jenny L. Byrne and Francisco Cervantes and Ekaterina Chelysheva and Richard E Clark and Hugues de Lavallade and Iryna S. Dyagil and Carlo Gambacorti-Passerini and John R. Goldman and İbrahim Celalettin Haznedaroğlu and Henrik Hjorth-Hansen and Tessa L Holyoake and Brian J P Huntly and Philipp D. le Coutre and E. G. Lomaia and Markus Pfirrmann and David Marin-Costa and Giovanni Martinelli and John E. Mayer and Dragana Milojkovi{\'c} and Eduardo Olavarr{\'i}a and Kimmo Porkka and Johan Richter and Philippe Rousselot and Giuseppe Saglio and Mine Hekimgil and Jesper Stentoft and Anna G Turkina and Paolo Vigneri and Andrey Zaritskey and A Oscar Aguayo and Manuel Antonio P{\'e}rez Ayala and Israel Bendit and Raquel Bengi{\'o} and Carlos Best and Eduardo Oscar Bullorsky and Eduardo de Fuentes Cervera and Carmino de-Souza and Ernesto Fanilla and David G{\'o}mez-Almaguer and Nelson Hamerschlak and Jos{\'e} Marey L{\'o}pez and Alicia E Magari{\~n}os and Luis Antonio Meillon and Jorge H. Milone and Beatriz Moiraghi and Ricardo Pasquini and Carolina Pavlovsky and Guillermo J Ruiz-Arg{\"u}elles and Neil L. Spector and Christopher Arthur and Peter J Browett and Andrew Grigg and Jianda Hu and Xiao-Jun Huang and Timothy P Hughes and Qian Jiang and Saengsuree Jootar and Dong-wook Kim and Hemant Malhotra and Pankaj Malhotra and Itaru Matsumura and Junia V. Melo and Kazunori Ohnishi and Ryuzo Ohno and Tapan K. Saikia and Anthony P. Schwarer and Naoto Takahashi and Constantine S Tam and Tetsuzo Tauchi and Kensuke Usuki and Jianxiang Wang and Fawzi Abdel-Latif Abdel-Rahman and Mahmoud Aljurf and Ali Bazarbachi and Dina Ben Yehuda and Naeem A. Chaudhri and Muheez Alani Durosinmi and Hossam Mohamed Kamel and Vernon Johan Louw and Bassam Francis Matti and Arnon Nagler and Pia Raanani and Ziad Salem},
  journal={Blood},
  year={2013},
  volume={121 22},
  pages={
          4439-42
        }
}
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound… CONTINUE READING

Similar Papers

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.

  • Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Effective medicine and the economy

  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Petition demands Novartis lower US Gleevec price. http://www.pharmalot.com/2012/ 05/petition-demands-novartis-lower-us-gleevecprice

E. Silverman
  • Accessed February
  • 2013
VIEW 1 EXCERPT

Justices to take up generic drug case

E. Wyatt
  • The New York Times. December
  • 2012
VIEW 1 EXCERPT

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 3 EXCERPTS

An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2009
VIEW 1 EXCERPT